Market News

Eli Lilly’s (NYSE: LLY) Retevmo Gets FDA Nod

Eli Lilly and Company (NYSE: LLY) announced on Thursday that the U.S. Food and Drug Administration (FDA) had granted approval to Retevmo (selpercatinib, 40 mg & 80 mg capsules) for adult patients with locally advanced or metastatic solid tumors.

Retevmo can be used in the treatment of transfection (RET) gene fusion where a piece of DNA fuses with another gene in patients with tumors.

The FDA also granted approval to Retevmo for the treatment of RET gene fusion in non-small cell lung cancer (NSCLC) in adult patients.

David Hyman, M.D., chief medical officer, Loxo at Lilly commented, “Retevmo is the first and only RET inhibitor to receive both tumor-agnostic accelerated approval and traditional approval in NSCLC, further supporting its ability to deliver meaningful clinical benefit for patients across diverse tumor types.”

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More